FTSV - Forty Seven, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
94.55
+0.08 (+0.08%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close94.47
Open94.30
Bid60.00 x 1300
Ask95.49 x 800
Day's range94.25 - 94.80
52-week range5.53 - 95.12
Volume1,555,104
Avg. volume1,594,908
Market cap4.553B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-2.40
Earnings date19 Mar 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est75.95
  • Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More
    Zacks

    Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More

    The biotech sector was in focus with new drug approvals, acquisitions and regular pipeline updates from quite a few companies.

  • Company News for Mar 3, 2020
    Zacks

    Company News for Mar 3, 2020

    Companies in the news are: FTSV, MINI, KPTI ATEC

  • Gilead to Buy Immuno-Oncology Company Forty Seven for $4.9B
    Zacks

    Gilead to Buy Immuno-Oncology Company Forty Seven for $4.9B

    Gilead (GILD) looks to strengthen its immuno-oncology research and development portfolio with the acquisition of Forty Seven.

  • Bloomberg

    Gilead to Buy Forty Seven for $4.9 Billion for Cancer Drug

    (Bloomberg) -- Gilead Sciences Inc. agreed to buy Forty Seven Inc. for about $4.9 billion to advance into one of the hottest areas of pharmaceutical research: cancer treatments that harness the immune system to fight tumors.Gilead will acquire Forty Seven for $95.50 per share in cash in a transaction cleared by both boards, the Foster City, California-based company said in a statement Monday. The price is a 96% premium to Forty Seven’s closing price Thursday, before Bloomberg News broke the news of Gilead’s approach. Forty Seven’s shares rose 62% to $93.79 at 10:02 a.m. in New York.Gilead’s hepatitis C franchise turned the company into a drug-industry giant, but sales of the treatments have slipped from their peak and the company has struggled to find new streams of revenue. The deal with Forty Seven complements its 2017 acquisition of Kite Pharma, bringing an experimental therapy that has potential to be the first in its class, said Chief Executive Officer Daniel O’Day.“It fits perfectly into our strategy of finding areas of big unmet medical need,” O’Day said.O’Day took the reins last March, saying one of his top priorities was to bolster Gilead’s drug pipeline.Menlo Park, California-based Forty Seven received interest from other potential suitors, Bloomberg reported last week, citing people familiar with the company. The agreed price for the Gilead takeover includes options and warrants.The company’s experimental medicine, called magrolimab, is a monoclonal antibody in early studies for several cancers affecting the blood and lymph nodes, including acute myeloid leukemia and diffuse large B-cell lymphoma.Kite’s experimental therapy, Yescarta, has struggled as both government and private health plans have balked at the high-price of the one-time treatment. But O’Day said he expects Forty Seven’s therapy will face less difficulty in the market.“Forty Seven is pursuing a more well-trodden path,” he said.The therapy targets a “do-not-eat-me” signal that allows cancer cells to avoid destruction. The drug blocks the signal, allowing the patient’s own immune system to engulf and eradicate the malignant cells.Forty Seven also has two experimental medicines that may soon enter clinical tests, including an antibody that could be combined with magrolimab.O’Day said that Gilead is actively hunting for more deals in both the immunology and virology spaces.Citigroup Inc. and JPMorgan Chase & Co. acted as joint financial advisers to Gilead. Centerview Partners LLC is acting as the Forty Seven’s financial adviser. Skadden, Arps, Slate, Meagher & Flom LLP served as Gilead’s legal counsel and Cooley LLP did the same for Forty Seven.(Updates with other Forty Seven medicines in eleventh paragraph and comments from CEO in fourth, eighth and twelfth paragraphs)\--With assistance from Ed Hammond and Nabila Ahmed.To contact the reporters on this story: Marthe Fourcade in Paris at mfourcade@bloomberg.net;Kristen V. Brown in San Francisco at kbrown340@bloomberg.netTo contact the editors responsible for this story: Eric Pfanner at epfanner1@bloomberg.net, Timothy Annett, Mark SchoifetFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Gilead buys Forty Seven for $4.9 billion to bolster cancer drug pipeline
    Reuters

    Gilead buys Forty Seven for $4.9 billion to bolster cancer drug pipeline

    Gilead shares were up 2.3% at $70.95 in early morning trading. The deal is expected to complement the portfolio of Kite Pharma Inc, which the company acquired for $12 billion in 2017, and comes at a time when sales of Gilead's hepatitis C drugs have seen a steep fall. "The deal is in line with the strategy CEO Daniel O'Day had laid out earlier in the year, but I think he and his management need to do something more impactful," Credit Suisse analyst Evan Seigerman told Reuters.

  • Business Wire

    Gilead to Acquire Forty Seven for $4.9 Billion

    Gilead Sciences, Inc. (Nasdaq: GILD) and Forty Seven, Inc. (Nasdaq: FTSV) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Forty Seven for $95.50 per share in cash. The transaction, which values Forty Seven at approximately $4.9 billion, was unanimously approved by both the Gilead and Forty Seven Boards of Directors and is anticipated to close during the second quarter of 2020, subject to regulatory approvals and other customary closing conditions.

  • Introducing Forty Seven (NASDAQ:FTSV), The Stock That Zoomed 178% In The Last Year
    Simply Wall St.

    Introducing Forty Seven (NASDAQ:FTSV), The Stock That Zoomed 178% In The Last Year

    Unless you borrow money to invest, the potential losses are limited. But when you pick a company that is really...

  • Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks
    Zacks

    Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks

    Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.

  • Here's Why We're Watching Forty Seven's (NASDAQ:FTSV) Cash Burn Situation
    Simply Wall St.

    Here's Why We're Watching Forty Seven's (NASDAQ:FTSV) Cash Burn Situation

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

  • Forty Seven, Inc. (FTSV) Q2 Earnings Call Transcript
    Motley Fool

    Forty Seven, Inc. (FTSV) Q2 Earnings Call Transcript

    FTSV earnings call for the period ending June 30, 2019.

  • Have Insiders Been Buying Forty Seven, Inc. (NASDAQ:FTSV) Shares?
    Simply Wall St.

    Have Insiders Been Buying Forty Seven, Inc. (NASDAQ:FTSV) Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

  • Forty Seven Inc. (FTSV) Q1 2019 Earnings Call Transcript
    Motley Fool

    Forty Seven Inc. (FTSV) Q1 2019 Earnings Call Transcript

    FTSV earnings call for the period ending March 31, 2019.

  • Top Ranked Momentum Stocks to Buy for April 25th
    Zacks

    Top Ranked Momentum Stocks to Buy for April 25th

    Top Ranked Momentum Stocks to Buy for April 25th

  • Could Forty Seven, Inc.'s (NASDAQ:FTSV) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Forty Seven, Inc.'s (NASDAQ:FTSV) Investor Composition Influence The Stock Price?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The big shareholder groups in Forty Seven, Inc. (NASDAQ:FTSV) have power over the company. Institutions will often hold...

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more